Johnson & Johnson Invests $400 Million in Stroke Prevention Company, Luminar

Johnson & Johnson has invested $400 million to acquire Laminar, a privately owned company located in the United States. Laminar specializes in the development of heart implant devices designed to minimize the risk of stroke.

Laminar will integrate with J&J’s Biosense Webster department as part of the finalized acquisition, which also includes possible research milestone incentives.

Laminar claims that their heart implant devices have a rotating motion feature to eradicate left atrial appendage, in contrast to other commercial implants that block the LAA from the bloodstream. The LAA is a small pouch in the left atrium of the heart that has been associated with blood clots and poses a risk of triggering a stroke.

According to J&J, 38m individuals worldwide suffer with atrial fibrillation. Closing the LAA is a crucial step in lowering the risk of a stroke for people unable to take blood thinners for an extended period.

Randy Lashinski, head executive of Laminar, stated, “For the millions of people living with atrial fibrillation, stroke risk is a major concern. The team at Laminar is driven by our vision to develop and deliver an innovative solution to help patients live without the fear of stroke or the need for long-term use of blood thinners.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.